A study found that switching from rituximab to biosimilar CT-P10 is safe and effective for patients with systemic lupus ...
The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar ...
On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which ...
Number 3: Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while ...
The FDA approved a new strength of a trastuzumab biosimilar; UnitedHealth will remove reference adalimumab from some ...
A retrospective study of a mandatory nonmedical switch in Canada found no significant differences in rates of treatment persistence, loss of response, or adverse events in patients with inflammatory ...
In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in the biosimilars landscape, coinciding with ongoing legal disputes in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback